A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Primary Objective
To assess the safety and tolerability of INCB057643 as monotherapy and in combination with ruxolitinib
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Brandon Mcmahon, MD
Study ID
Protocol Number: 22-0130
More information available at ClinicalTrials.gov: NCT04279847
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers